Chronic spontaneous urticaria (CSU) is a condition defined by the presence of recurrent urticaria, angioedema, or both, which persist for more than six weeks in duration and occurs in the absence of an identifiable trigger. Both children and adults can develop CSU, although it is more common in adults and in women than in men, with a peak occurrence in the third to fifth decades of life. It imposes a significant burden on patients, families and healthcare systems. The goal of therapy in patients with CSU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. The recent introduction of biologic drugs has changed the management of the disease. This work aims to provide a narrative review of the current state of biological therapy and the promising drugs under development for CSU.

Biologic drugs in chronic spontaneous urticaria / Licari, A.; Manti, S.; Leonardi, S.; Minasi, D.; Caffarelli, C.; Cardinale, F.; Miraglia Del Giudice, M.; Calvani, M.; Ciprandi, G.; Marseglia, G. L.. - In: ACTA BIOMEDICA. - ISSN 2531-6745. - 92:7(2021), p. e2021527. [10.23750/abm.v92iS7.12415]

Biologic drugs in chronic spontaneous urticaria

Caffarelli C.;
2021-01-01

Abstract

Chronic spontaneous urticaria (CSU) is a condition defined by the presence of recurrent urticaria, angioedema, or both, which persist for more than six weeks in duration and occurs in the absence of an identifiable trigger. Both children and adults can develop CSU, although it is more common in adults and in women than in men, with a peak occurrence in the third to fifth decades of life. It imposes a significant burden on patients, families and healthcare systems. The goal of therapy in patients with CSU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. The recent introduction of biologic drugs has changed the management of the disease. This work aims to provide a narrative review of the current state of biological therapy and the promising drugs under development for CSU.
2021
Biologic drugs in chronic spontaneous urticaria / Licari, A.; Manti, S.; Leonardi, S.; Minasi, D.; Caffarelli, C.; Cardinale, F.; Miraglia Del Giudice, M.; Calvani, M.; Ciprandi, G.; Marseglia, G. L.. - In: ACTA BIOMEDICA. - ISSN 2531-6745. - 92:7(2021), p. e2021527. [10.23750/abm.v92iS7.12415]
File in questo prodotto:
File Dimensione Formato  
21 10 licari caffarelli biologics chronic urtic.pdf

accesso aperto

Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 428.95 kB
Formato Adobe PDF
428.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2910413
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact